Lung Cancer

Here is a list of some recent trials that launched within the cancer space in January.

Tecentriq with carboplatin and etoposide led to a median overall survival rate of 12.3 months versus 10.3 months in those assigned placebo, carboplatin and etoposide, although the death rate was high at a median follow-up of 22.9 months.

Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.

Patients with ALK-positive non-small-cell lung cancer who received Lorbrena reported better quality of life and had longer progression-free survival than patients who received Xalkori.

The FDA based its decision on data that demonstrated that the novel therapy in combination with Tecentriq induced a higher overall response to therapy compared to Tecentriq alone in patients with PD-L1-positive non-small cell lung cancer.

The FDA granted a priority review to the supplemental new drug application for Lorbrena for the firstline treatment of ALK-positive metastatic non-small cell lung cancer.

The company has withdrawn the small cell lung cancer indication for Opdivo (nivolumab) based on discussions with the FDA, particularly focused on post-market studies that missed their primary endpoints of overall survival.

In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.

Mortality rate for patients with cancer decreases due to Medicaid expansion for patients with newly diagnosed breast, colorectal and lung cancer.

Dr. Sally J. York goes over the types of immunotherapy-related side effects, and what patients with lung cancer and their caregivers should look out for.

The decision was based on data that demonstrated sotorasib induced anticancer activity and achieved a positive benefit-risk profile in patients with locally advanced or metastatic non-small cell lung cancer whose disease harbors a KRAS G12C mutation.

This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.

As treatment delays become more common – especially with the COVID-19 pandemic – delays as much as four weeks can impact the risk for mortality in seven different types of cancer.

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!

A new grant program offers financial assistance for patients with mesothelioma who must travel for cancer care.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for November 2020.

Living with cancer is not dissimilar to the challenges the COVID-19 pandemic is presenting all of us, but living with cancer during this pandemic is a challenge all to itself, a tough balancing act to pull off.

Drugs that target certain gene mutations are improving survival rates for patients with lung cancer.

Patients with mesothelioma are living longer thanks to new drug combinations – including the first FDA-approved regimen in 15 years.

As our understanding of lung cancer broadens, experts are now looking to rare genomic alterations that lead to aggressive lung cancer.

Patients with lung cancer should take all recommended precautions against COVID-19, but they must also keep up with their cancer care, doctors advise.

Bonnie Addario, a 16-year lung cancer survivor, shares a message of hope and invites you to ‘The Living Room.’

CURE® spoke with Dr. David Cooke, on behalf of the American Lung Association, on addressing racial disparities in lung cancer screening and care.

Among patients with extensive-stage small cell lung cancer, several groups were found to receive chemotherapy less often compared with White patients. They included Black, older and uninsured patients as well as those with nonprivate health insurance.